Matt Kaeberlein

Kaeberlein has articulated a clear and durable future vision centered on targeting aging as a core preventive-medicine strategy, paired with concrete translational paths: systematic longevity-intervention screening, explicit large-scale discovery goals, and randomized trials of rapamycin in companion dogs. The evidence is unusually specific for this dimension, though it is framed more as geroscience and healthspan/lifespan extension than as an explicit promise to end aging outright.

Primary citation metrics show very strong, field-shaping scientific impact in aging biology. An h-index of 81, 33,489 total citations, and multiple highly cited papers on Sir2/sirtuins, TOR/mTOR signaling, calorie restriction, and yeast lifespan indicate influence on core technical agendas in longevity research, not merely high publication volume.

The evidence shows longevity-focused institution-building roles, but no disclosed personal investments, donations, fund allocations, or concrete capital amounts attributable to Kaeberlein. Because capital deployment appears relevant through Optispan/Ora/LongeVC roles, this is not N/A, but the actual deployed-capital evidence is very thin.

Strategic taste applies, but the provided evidence supports only moderate strategic signal. Kaeberlein appears to have made coherent organization-building bets around aging biology, translational geroscience, dog aging, and rapamycin/mTOR-adjacent healthspan work. Founding/directing major longevity initiatives suggests field-building judgment, but the evidence does not show a clearly articulated thesis, early contrarian positioning, counterfactual importance, capital allocation record, or documented rationale strong enough for a high score.

Field creation applies because the evidence attributes two longevity-relevant organization/program roles to Kaeberlein, including co-founding Ora Biomedical and serving as first director of the Dog Aging Project. However, the structured facts say neither organization is active, and the independent sources provided mainly show scientific participation rather than corroborating the specific field-building achievements or their downstream impact. Under the independence gate, the score should not exceed 5 without primary or independent corroboration of those organization-building claims.

There is credible but limited evidence of public conviction: Kaeberlein attached his name to off-label rapamycin healthspan research and to an ambitious million-intervention longevity testing proposal. This supports moderate bravery through controversial-position and big-bet flavors, but the evidence does not show major personal downside, sustained criticism, career sacrifice, or self-experimentation, so it falls well short of field-defining bravery.

Evidence supports meaningful second-order leverage through organization-building and broad scientific influence: Kaeberlein founded or led two longevity-relevant organizations/projects and has very high citation reach, suggesting his work has helped mobilize collaborators and follow-on research. However, the evidence is thin on concrete downstream outcomes such as capital attracted, policy influence, startup creation by others, major public legitimacy effects, or documented talent pipelines, so this is not field-defining on the provided record.